Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CombinatoRx to Present at Baird's 2006 Focus on Oncology Conference.


CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: CRXX) today announced that Alexis Borisy, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , is scheduled to present a corporate update at the upcoming Baird's Focus on Oncology Conference to be held at the Four Seasons Hotel in New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
. Mr. Borisy is scheduled to present on August 2, 2006 at 10:05 a.m. EST EST electroshock therapy.

EST
abbr.
electroshock therapy
. Interested parties may access the live webcast of the presentation by visiting the CombinatoRx website at www.combinatorx.com.

About CombinatoRx

CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, metabolic disease metabolic disease,
n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis.

paraneoplastic syndrome 
, neurodegenerative disease Neurodegenerative disease
A disease in which the nervous system progressively and irreversibly deteriorates.

Mentioned in: Amnesia
, and infectious disease Infectious disease

A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions.
. We are currently developing a portfolio of five product candidates targeting multiple diseases which were discovered by applying our proprietary screening technology. For further information, please visit the CombinatoRx website at www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995 concerning CombinatoRx, its plans for its product candidates and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2006 CombinatoRx, Incorporated. All rights reserved.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 26, 2006
Words:366
Previous Article:New York Community Bancorp, Inc. Reports 2nd Quarter 2006 Diluted Cash EPS of $0.26 & Diluted Operating EPS of $0.24, Excluding a Post-Merger...
Next Article:OXiGENE Reports Second-Quarter 2006 Operational and Financial Results.



Related Articles
CombinatoRx to Present at the BIO CEO & Investor Conference.
CombinatoRx to Present at the BioCentury Future Leaders Conference.
CombinatoRx to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference.
CombinatoRx to Present at the BIO 2006 Chicago Annual International Convention.
CombinatoRx Appoints Lynn Baird, Ph.D., as Senior Vice President of Regulatory Affairs, QA/QC.
CombinatoRx to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference.
BERLEX JOINS STRATEGIC DIAGNOSTICS IN ANTIBODY EFFORT.
CombinatoRx to Present at the Pacific Growth Equities Life Sciences Growth Conference.
CombinatoRx to Present at the Jefferies Life Sciences Conference.
Chugai Pharmaceutical to Establish an Oncology Unit.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles